Information:
Fel:
ID
34586
Beskrivning
Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01257451
Länk
https://clinicaltrials.gov/show/NCT01257451
Nyckelord
Versioner (1)
- 2019-01-19 2019-01-19 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
19 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Type 2 Diabetes Mellitus NCT01257451
Eligibility Type 2 Diabetes Mellitus NCT01257451
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetes Mellitus NCT01257451
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
age: ≥ 70 years inclusive at visit 1.
boolean
ID.2
Item
patients with a confirmed diagnosis of t2dm
boolean
ID.3
Item
hba1c of ≥ 7% and ≤10.0% by central laboratory at visit 1 and assessed by the investigator to be inadequately controlled
boolean
ID.4
Item
body mass index (bmi) in the range of 19-45kg/m2
boolean
ID.5
Item
fpg ≥ 270 mg/dl (≥ 15.0 mmol/l)
boolean
ID.6
Item
previous or current participation in any vildagliptin clinical study.
boolean
ID.7
Item
history of hypersensitivity to dpp-4 inhibitors.
boolean
ID.8
Item
concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.
boolean
ID.9
Item
donation of blood or significant blood loss equaling to at least one unit of blood within the past 2 weeks of start of study or a blood transfusion within the past 12 weeks or planned regular transfusions during the study period other protocol-defined inclusion/exclusion criteria may apply
boolean